central nervous system disorders

Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term....

The FDA has granted Fast Track designation to Edgewise Therapeutics Inc's (NASDAQ: EWTX) EDG-5506 for Becker Muscular Dystrophy (BMD). EDG-5506, a selective, small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in DMD and BMD....

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the American Society of Gene and Cell Therapy. Data demonstrate durable expression...